Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Macy's Inc (M) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Macy's Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.75 (market cap $4.49B), while Macy's Inc trades at $22.45 (market cap $6.08B). The key difference: Macy's Inc is the larger of the two by market cap, and Macy's Inc pays a 3.31% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | M | |
|---|---|---|
Market Cap | $4.49B | $6.08B |
Sector | Health | Consumer Cyclical |
52-Week High | $28.06 | $25.96 |
52-Week Low | $20.06 | $11.90 |
Enterprise Value | $3.69B | $9.90B |
Dividend Yield | — | 3.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
Macy's (M) trades at $23.13, down 0.52% on the day, with technical indicators showing a bullish trend supported by moving averages. The stock shows attractive valuation metrics with a P/E of 9.79 and P/S of 0.29, while recent earnings have consistently beaten expectations. The company's 'Bold New Chapter' strategy is gaining traction with improved comparable sales and digital growth, supported by Berkshire Hathaway's new 3.04 million-share position disclosed in Q1 2026.
Macy's presents a compelling value opportunity with strong institutional interest and operational improvements, though investors face risks from retail sector headwinds and margin pressure. The consensus price target of $23.80 suggests modest upside potential, while execution on turnaround initiatives remains critical for sustained growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Macy's Inc
Founded in 1858 and based in New York City, Macy's operates 570 stores under the Macy's nameplate, 58 stores under the Bloomingdale's nameplate, and 160 freestanding Bluemercury specialty beauty stores (as of the end of fiscal-year 2021). Macy's also operates e-commerce sites and licenses two Bloomingdale's stores in the United Arab Emirates and Kuwait. Women's apparel, accessories, shoes, cosmetics, and fragrances comprised 59% of Macy's 2021 sales.
Read more on M →
